Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Breast cancer risk dramatically reduced with osteoporosis drug
May 18th, 2006
The Pennsylvania Breast Cancer Coalition (PBCC) salutes the National Surgical Adjuvant Breast and Bowel Project (NSABP) for their breakthrough discovery in the Study of Tamoxifen and Raloxifene (STAR) clinical trial, which demonstrates the success of raloxifene (Evista) in reducing breast cancer risk for postmenopausal women at increased risk of the disease with fewer side effects than tamoxifen. Raloxifene (Evista) is currently prescribed for osteoporosis. "These results indicate an important and significant breakthrough in our ongoing battle with breast cancer, and serve as an example of the value of clinical trials in breast cancer research and...
Source: Biotech Business Week (2006-05-18)
|
